260 related articles for article (PubMed ID: 2297828)
1. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
2. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
3. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Sabatine MS; Tu TM; Jang IK
J Thromb Thrombolysis; 2000 Oct; 10(2):189-96. PubMed ID: 11005941
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
7. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
Schneider J
Thromb Res; 1991 Dec; 64(6):677-89. PubMed ID: 1798957
[TBL] [Abstract][Full Text] [Related]
8. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Imura Y; Stassen JM; Collen D
J Pharmacol Exp Ther; 1992 Jun; 261(3):895-8. PubMed ID: 1602394
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban.
Kawai H; Yamamoto T; Hara H; Tamao Y
Thromb Res; 1994 May; 74(3):185-91. PubMed ID: 8042187
[TBL] [Abstract][Full Text] [Related]
11. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
13. The effect of thrombin inhibition in a rat arterial thrombosis model.
Broersma RJ; Kutcher LW; Heminger EF
Thromb Res; 1991 Nov; 64(4):405-12. PubMed ID: 1788827
[TBL] [Abstract][Full Text] [Related]
14. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Mellott MJ; Connolly TM; York SJ; Bush LR
Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D
Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006
[TBL] [Abstract][Full Text] [Related]
16. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1988 May; 85(9):3184-8. PubMed ID: 3362867
[TBL] [Abstract][Full Text] [Related]
17. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Yamashita T; Yamamoto J; Sasaki Y; Matsuoka A
Thromb Res; 1993 Jan; 69(1):93-100. PubMed ID: 8465278
[TBL] [Abstract][Full Text] [Related]
18. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons.
Lumsden AB; Kelly AB; Schneider PA; Krupski WC; Dodson T; Hanson SR; Harker LA
Blood; 1993 Apr; 81(7):1762-70. PubMed ID: 8461462
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Schumacher WA; Heran CL; Steinbacher TE
J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
